ReviewBiologics : targets & therapy2021
Biologic Treatments of Psoriasis: An Update for the Clinician.
Review in Biologics : targets & therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Integration of GWAS and single-cell analysis for psoriasis identifies disease-associated cell subtypes and therapeutic targets.Nature communications · 2026Pooled it
- Efficacy and safety of mirikizumab (LY3074828) in chronic plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.Frontiers in medicine · 2025Pooled it
- Pooled it
- Criteria used to define tumor necrosis factor-alpha inhibitors failure in patients with moderate-to-severe psoriasis: a systematic literature review.Annals of medicine · 2023Pooled it
- Biomarkers in Pemphigus Vulgaris: A Systematic Review.Journal of cutaneous medicine and surgeryPooled it
- Cutaneous and systemic improvements in psoriasis patients after different biologic treatments in a real-world longitudinal prospective study.Scientific reports · 2025Trial
- Real-World Effectiveness and Safety of Ixekizumab in Moderate-to-Severe Plaque Psoriasis in the Indian Population: A Pilot Study.Indian dermatology online journal · 2026Article
- Safety and Efficacy of Adalimumab Biosimilar in Psoriasis and Hidradenitis Suppurativa:Saudi medical journal · 2026Observational
- Transcriptomic Profiling of Psoriatic Lesions by Tape-Stripping Reveals Site-Specific Differences.Journal of clinical medicine · 2026Article
- Nanocarriers, Smart Biomaterials and Emerging Therapeutics for Psoriasis: Current Progress and Future Directions.AAPS PharmSciTech · 2026Review
- Molecular Diagnostics in Hand Dermatoses: Clinical Findings and Health-Related Quality of Life in a 3-Year Follow-Up Cohort Study.Dermatology and therapy · 2026Article
- Microneedle Technology in Psoriasis Management: Mechanistic Insights, Technological Innovation, Clinical Progress, and Challenges.Advanced healthcare materials · 2026Review
- Article
- Biological Treatment of Psoriasis-Data So Far.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Exploratory Retrospective Assessment of Patients with Psoriasis Receiving Biological Therapy.Medicina (Kaunas, Lithuania) · 2026Article
- Real-World Dose Adjustment and Switching of Interleukin-17/23 Inhibitors for Thai Psoriasis.Dermatology research and practice · 2026Article
- Real-world evidence for repurposing hydralazine as a potential epigenetic modulator for psoriasis: a 16-year retrospective nationwide cohort study.Journal of translational medicine · 2025Article
- Tracing Five Decades of Psoriasis Pharmacotherapy: A Large-Scale Bibliometric Investigation with AI-Guided Terminology Normalization.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Effects of Betulinic Acid and Ursolic Acid on IL-17-Induced CCL20 Release in Normal Human Epidermal Keratinocytes.Life (Basel, Switzerland) · 2025Article
- Single-Nucleus Chromatin Accessibility and Epigenetic Study Uncover Cell States and Transcriptional Regulation of Epidermis in Hidradenitis Suppurativa.Biomedicines · 2025Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of biologic agents within the past two decades has dramatically improved the treatment of psoriasis and psoriatic arthritis. Given that there now exists 11 FDA approved biologic options available for psoriasis, with more in the pipeline, the therapeutic armamentarium has been greatly enhanced. However, the fact that there are so many available options has also caused confusion for providers. Therefore, this manuscript deliberately focuses on the most clinically useful facts (such as efficacy and safety data) about each and every FDA approved biologic agent (including pipeline agents) for psoriasis. Moreover, among the clinically relevant facts, this manuscript purposely emphasizes the unique merits and demerits of each agent to make it easier for the provider to select which one of these many options is the best for the particular patient on hand. The goal of this manuscript is to aid the busy practicing dermatologist in becoming more adept at using these agents with the ultimate aim of improving patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.